Gal-3和Chemerin与冠心病的研究进展
Research Progress of Gal-3 and Chemerin in Coronary Heart Disease
DOI: 10.12677/acm.2025.1561829, PDF,   
作者: 张 群, 廖志雄*：吉首大学医学院，湖南 吉首；张家界市人民医院心血管内科，湖南 张家界；丁建平：张家界市人民医院心血管内科，湖南 张家界；杜利平：吉首大学医学院，湖南 吉首
关键词: 冠心病；半乳糖凝集素-3；趋化素；冠状动脉粥样硬化；Coronary Heart Disease； Galectin-3； Chemerin； Coronary Atherosclerosis
摘要: 冠心病(CHD)是全球范围内的主要心血管疾病死亡原因之一，其危害性不容忽视，近年来，研究显示半乳糖凝集素-3 (Gal-3)和趋化素(Chemerin)作为两种重要的心血管生物标志物在冠心病研究中受到了广泛关注。Gal-3在冠状动脉粥样硬化和斑块稳定性中发挥着重要作用，通过调节炎症反应、细胞增殖和凋亡等机制影响冠心病的发生和发展。Chemerin则主要通过调控脂肪代谢、炎症反应和血管内皮功能等途径参与冠心病的发展进程。本研究综述了Gal-3和Chemerin的基本特征及其在冠心病中的作用机制，同时探讨了它们在冠心病诊断、治疗及预后评估中的潜在应用价值，为冠心病的防治提供新的思路和方法。
Abstract: Coronary heart disease (CHD) is one of the leading causes of cardiovascular disease mortality worldwide, and its severity cannot be overstated. In recent years, studies have demonstrated that Galectin-3 (Gal-3) and Chemerin, as two important cardiovascular biomarkers, have garnered significant attention in CHD research. Gal-3 plays an important role in coronary atherosclerosis and plaque stability. It influences the occurrence and development of coronary heart disease by regulating inflammatory reaction, cell proliferation and apoptosis. Chemerin participates in the development of coronary heart disease by regulating lipid metabolism, inflammatory reaction and vascular endothelial function. In this study, we reviewed the basic characteristics of Gal-3 and Chemerin and their mechanisms of action in coronary heart disease, and discussed their potential application value in the diagnosis, treatment and prognosis evaluation of coronary heart disease, to provide new ideas and methods for the prevention and treatment of coronary heart disease.
文章引用：张群, 丁建平, 杜利平, 廖志雄. Gal-3和Chemerin与冠心病的研究进展[J]. 临床医学进展, 2025, 15(6): 1095-1100. https://doi.org/10.12677/acm.2025.1561829

参考文献

[1] Voutilainen, A., Brester, C., Kolehmainen, M. and Tuomainen, T. (2023) What Is the Most Appropriate Follow-Up Time for Detecting the Epidemiological Relationship between Coronary Artery Disease and Its Main Risk Factors: Novel Findings from a 35-Year Follow-Up Study. Coronary Artery Disease, 34, 320-331. [Google Scholar] [CrossRef] [PubMed]
[2] Bunker, G.K., Patidar, M., Atal, D. and Meena, R.L. (2022) Evaluation of Risk Factors of Premature Coronary Artery Disease in Patients from North India: A Rising Epidemic. Indian Journal of Clinical Cardiology, 3, 183-187. [Google Scholar] [CrossRef] 
[3] 孟利民, 杨华, 常超,等. 急性ST段抬高型心肌梗死患者血清趋化素水平与血栓负荷相关性的探讨[J]. 临床心血管病杂志, 2019, 35(2): 137-141.
[4] 杜发旺, 陈丹丹, 吴玥婷, 等. 人半乳糖凝集素-3与急性心肌梗死患者梗死范围冠脉内血栓负荷及心室重塑的关系研究[J]. 中国实用内科杂志, 2019, 39(11): 985-990.
[5] Zhou, X., Su, J., Zhang, C., Dai, H. and Wang, W. (2024) Decreased Expression of Galectin-3 in the Epidermis of Psoriasis Patients. European Journal of Dermatology, 34, 371-377. [Google Scholar] [CrossRef] [PubMed]
[6] Comeglio, P., Guarnieri, G., Filippi, S., Cellai, I., Acciai, G., Holyer, I., et al. (2024) The Galectin-3 Inhibitor Selvigaltin Reduces Liver Inflammation and Fibrosis in a High Fat Diet Rabbit Model of Metabolic-Associated Steatohepatitis. Frontiers in Pharmacology, 15, Article 1430109. [Google Scholar] [CrossRef] [PubMed]
[7] 朱玉洁, 仲琳, 杨军. 半乳糖凝集素-3、白介素-6、单核细胞趋化蛋白-1与动脉粥样硬化斑块稳定性的相关性研究[J]. 解放军医药杂志, 2017, 29(12): 39-41.
[8] Di Gregoli, K., Somerville, M., George, S.J., MacDonald, R., Jackson, C.L. and Johnson, J.L. (2016) Galectin-3 Regulates Macrophage Behaviour and Modulates Atherosclerotic Plaque Compostion. Atherosclerosis, 244, e5. [Google Scholar] [CrossRef] 
[9] Wilson, J.M., Nguyen, A.T., Schuyler, A.J., Commins, S.P., Taylor, A.M., Platts-Mills, T.A.E., et al. (2018) Ige to the Mammalian Oligosaccharide Galactose-α-1, 3-Galactose Is Associated with Increased Atheroma Volume and Plaques with Unstable Characteristics—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 38, 1665-1669. [Google Scholar] [CrossRef] [PubMed]
[10] 许名东, 李丽华, 李晚泉,等. 半乳糖凝集素-3通过lncARSR影响小鼠冠状动脉粥样硬化易损斑块稳定的机制[J]. 南方医科大学学报, 2021, 41(7): 1067-1072.
[11] 梁天, 李飞, 刘超. 内皮细胞功能障碍与动脉粥样硬化的研究进展[J]. 中华老年心脑血管病杂志, 2024, 26(12): 1504-1507.
[12] Zhang, C., Li, H. and Han, M. (2023) Effect of Atrial Fibrillation on Plasma Galectin-3 and Soluble CD40 Ligand Levels in Patients with Ischemic Cardiomyopathy. Journal of International Medical Research, 51, 1-9. [Google Scholar] [CrossRef] [PubMed]
[13] 贾丽娜, 朱晓峰, 尹昌浩. Gal-3在动脉粥样硬化性疾病中的研究进展[J]. 牡丹江医学院学报, 2023, 44(1): 130-132.
[14] 潘婷婷. 螺内酯对心梗后大鼠半乳糖凝集素-3基因表达及改善心脏纤维化机制研究[D]: [硕士学位论文]. 苏州: 苏州大学, 2017.
[15] 谢昊, 董阳, 莫崇念, 等. 不同程度冠脉病变冠心病患者血清亲环素A、可溶性生长刺激表达基因2蛋白、基质金属蛋白酶-29水平变化及其诊断价值分析[J]. 陕西医学杂志, 2024, 53(7): 949-953.
[16] Man, A.W.C., Zhou, Y.W., et al. (2023) Deletion of Adipocyte NOS3 Potentiates High-Fat Diet-Induced Hypertension and Vascular Remodeling via Chemerin. Cardiovascular Research, 119, 2755-2769.
[17] Wabel, E., Orr, A., Flood, E.D., Thompson, J.M., Xie, H., Demireva, E.Y., et al. (2023) Chemerin Is Resident to Vascular Tunicas and Contributes to Vascular Tone. American Journal of Physiology-Heart and Circulatory Physiology, 325, H172-H186. [Google Scholar] [CrossRef] [PubMed]
[18] Wang, J., Wang, X., Xu, Z., Zhang, Y., Xue, D., Zhu, R., et al. (2022) Chemerin-9 in Paraventricular Nucleus Increases Sympathetic Outflow and Blood Pressure via Glutamate Receptor-Mediated ROS Generation. European Journal of Pharmacology, 936, Article ID: 175343. [Google Scholar] [CrossRef] [PubMed]
[19] 于国慧, 张诺琪, 张欣媛, 等. 脂肪因子chemerin与心血管疾病的关系研究进展[J]. 河北医学, 2023, 29(9): 1579-1582.
[20] 张凯歌, 张燕子, 陈静,等. 冠心病患者血清Alarin和Chemerin的表达水平与血管病变严重程度的相关性研究[J]. 现代生物医学进展, 2022, 22(24): 4686-4690.
[21] Tan, L., Wang, N., Galema‐Boers, A.M.H., van Vark‐van der Zee, L., van Lennep, J.R., Mulder, M.T., et al. (2024) Statins, but Not Proprotein Convertase Subtilisin‐Kexin Type 9 Inhibitors, Lower Chemerin in Hypercholesterolemia via Low‐Density Lipoprotein Receptor Upregulation. MedComm, 5, e681. [Google Scholar] [CrossRef] [PubMed]
[22] Tang, C., Chen, G., Wu, F., Cao, Y., Yang, F., You, T., et al. (2023) Endothelial CCRL2 Induced by Disturbed Flow Promotes Atherosclerosis via Chemerin-Dependent Β2 Integrin Activation in Monocytes. Cardiovascular Research, 119, 1811-1824. [Google Scholar] [CrossRef] [PubMed]
[23] Hartmann, L., Buschmann, K., Reifenberg, G., Wojnowski, L., Treede, H., Li, H., et al. (2024) Comparison of Adipokines Expression in Adipose Tissues of Patients with Coronary Artery Disease—Role of Chemerin. Atherosclerosis, 395, Article ID: 117712. [Google Scholar] [CrossRef] 
[24] Ismaiel, A., Ashfaq, M.Z., Leucuta, D., Ismaiel, M., Ensar Ismaiel, D., Popa, S., et al. (2022) Chemerin Levels in Acute Coronary Syndrome: Systematic Review and Meta-Analysis. Laboratory Medicine, 53, 552-560. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, B., Kou, W., Ji, S., Shen, R., Ji, H., Zhuang, J., et al. (2022) Prognostic Value of Plasma Adipokine Chemerin in Patients with Coronary Artery Disease. Frontiers in Cardiovascular Medicine, 9, Article 968349. [Google Scholar] [CrossRef] [PubMed]
[26] 黄博雅, 柏松, 李津, 等. 血清趋化素和半乳糖凝集素3水平对心房颤动并发左心房纤维化有预测价值[J]. 内科急危重症杂志, 2024, 30(1): 43-46, 92.

为你推荐